By vgreene, 10 October, 2020 Effect of Regular Intravenous Immunoglobulin Therapy on Prognosis of Severe Pneumonia in Patients With COVID-19; <a href=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151471/><b><u>access <i> J Infect<i> article</u></b></a>
By vgreene, 10 October, 2020 High-Dose IVIG as a Therapeutic Option for Deterioriating Patients With Coronavirus Disease 2019; <a href=https://academic.oup.com/ofid/article/7/3/ofaa102/5810740><b><u>access <i>Open Forum Infect Dis</i> article</u></b></a>
By vgreene, 10 October, 2020 <b>Study considerations:</b> retrospective; treatment bias; IVIG timing, dosing, and duration varied among sites
By vgreene, 10 October, 2020 No significant difference in 28-day in-hospital mortality (13% in both groups) or 60-day in-hospital mortality (19% IVIG, 14% non-IVIG); IVIG group had longer LOS (23.5 vs 16 days) and longer dz duration (31 vs 23 days)
By vgreene, 10 October, 2020 Retrospective study; 325 hospitalized pts (mean age, 58y) w/ confirmed SARS-CoV-2 (68% severe, 32% critical); 174 pts received IVIG 0.1-0.5 g/kg daily x5-15 days, 151 pts received SOC only; IVIG pts had more severe dz (higher APACHE II, SOFA scores, O<sub
By vgreene, 10 October, 2020 Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients With COVID 19 A Multicenter Retrospective Cohort Study
